Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of the study is to assess the safety and efficacy of once daily itacitinib oral administration in participants with diffuse large B-cell lymphoma (DLBCL) who will receive CAR-T cell therapy with axicabtagene ciloleucel (axi-cel).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznanie chłoniaka rozlanego z dużych komórek B
- •Wiek 18 lat lub więcej
- •Kwalifikacja do terapii CAR-T
- •Wysoki wskaźnik ferytyny (powyżej 400) i białka C-reaktywnego (powyżej 2) w badaniach
- •Dobry ogólny stan zdrowia (skala ECOG 0-2)
- •Zdolność do zrozumienia i podpisania zgody na udział w badaniu
- •Kobiety i mężczyźni w wieku rozrodczym muszą stosować niezawodną antykoncepcję
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Moffitt Cancer Center
Tampa, United States
Trial contact
Kelsey Lee
Michael Jain, MD, PhD
PRINCIPAL_INVESTIGATOR
Julio Chavez, MD, MS
SUB_INVESTIGATOR
Rawan Faramand, MD
SUB_INVESTIGATOR
Farhad Khimani, MD
SUB_INVESTIGATOR
Aleksandr Lazaryan, MD, MPH, PhD
SUB_INVESTIGATOR
Hien Liu, MD
SUB_INVESTIGATOR
Frederick Locke, MD
SUB_INVESTIGATOR
Taiga Nishihori, MD
SUB_INVESTIGATOR
Javier Pinilla, MD, PhD
SUB_INVESTIGATOR
Bijal Shah, MD, MS
SUB_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.